Skip to content
Olorinab
Olorinab is a small molecule pharmaceutical. It is currently being investigated in clinical studies. The pharmaceutical is active against cannabinoid receptor 2. In addition, it is known to target cannabinoid receptor 1.
Download report
Favorite
Commercial
Therapeutic Areas
No data
Trade Name
FDA
EMA
No data
Drug Products
FDA
EMA
New Drug Application (NDA)
New Drug Application (NDA)
Abbreviated New Drug Application (ANDA)
Abbreviated New Drug Application (ANDA)
No data
Labels
FDA
EMA
No data
Indications
FDA
EMA
No data
Agency Specific
FDA
EMA
No data
Patent Expiration
No data
ATC Codes
No data
HCPCS
No data
Clinical
Clinical Trials
3 clinical trials
View more details
Mock data
Subscribe for the real data
Indications Phases 4
No data
Indications Phases 3
No data
Indications Phases 2
Indication
MeSH
Ontology
ICD-10
Ph 1
Ph 2
Ph 3
Ph 4
Other
Total
Irritable bowel syndromeD043183EFO_0000555K5811———2
Crohn diseaseD003424EFO_0000384K50—1———1
Abdominal painD015746R10.9—1———1
Indications Phases 1
No data
Indications Without Phase
No data
Epidemiology
Epidemiological information for investigational and approved indications
View more details
Drug
General
Drug common nameOLORINAB
INNolorinab
Description
Olorinab (APD371) is a drug being developed by Arena Pharmaceuticals for the treatment of gastrointestinal pain associated with Crohn's disease and irritable bowel syndrome. It acts as a potent and selective cannabinoid CB2 receptor agonist and is claimed to be orally active and peripherally selective. Initial Phase IIa exploratory clinical trials have been successful in patients with quiescent Crohn's disease. Arena initiated the Phase IIb Captivate trial in late July 2019 in patients with irritable bowel syndrome related pain, in constipation and diarrhea predominant sub-types. The Phase IIb trial is expected to enroll 240 participants between the ages of 18 and 70.Three doses of 10 mg, 25 mg, and 50 mg are being tested against Placebo in a 3:4 prescription ratio with a Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor) masking layout.
Classification
Small molecule
Drug classcannabinol derivatives
Image (chem structure or protein)
Structure (InChI/SMILES or Protein Sequence)
CC(C)(C)[C@@H](CO)NC(=O)c1nn(-c2c[n+]([O-])ccn2)c2c1C[C@@H]1C[C@H]21
Identifiers
PDB—
CAS-ID1268881-20-4
RxCUI—
ChEMBL IDCHEMBL4175981
ChEBI ID—
PubChem CID60164925
DrugBankDB14998
UNII ID581F7DFA9B (ChemIDplus, GSRS)
Target
Agency Approved
CNR2
CNR2
Organism
Homo sapiens
Gene name
CNR2
Gene synonyms
CB2A, CB2B
NCBI Gene ID
1269
Protein name
cannabinoid receptor 2
Protein synonyms
cannabinoid receptor 2 (macrophage), CX5
Uniprot ID
Q6NSY0
Mouse ortholog
Cnr2 (12802)
cannabinoid receptor 2 (Q544H5)
Alternate
CNR1
CNR1
Organism
Homo sapiens
Gene name
CNR1
Gene synonyms
CNR
NCBI Gene ID
1268
Protein name
cannabinoid receptor 1
Protein synonyms
CANN6, cannabinoid receptor 1 (brain), central cannabinoid receptor
Uniprot ID
Q9UNN0
Mouse ortholog
Cnr1 (12801)
cannabinoid receptor 1 (Q5SF33)
Variants
Clinical Variant
No data
Financial
No data
Trends
PubMed Central
Top Terms for Disease or Syndrome:
Mock data
Subscribe for the real data
Additional graphs summarizing 26 documents
View more details
Safety
Black-box Warning
No Black-box warning
Adverse Events
Top Adverse Reactions
0 adverse events reported
View more details